Drug General Information
Drug ID
D03MYX
Former ID
DIB007762
Drug Name
AM0010
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [524564]
Company
Armo biosciences
Target and Pathway
Target(s) Interleukin-10 Target Info Modulator [550272]
KEGG Pathway Cytokine-cytokine receptor interaction
FoxO signaling pathway
Jak-STAT signaling pathway
T cell receptor signaling pathway
Intestinal immune network for IgA production
Pertussis
Leishmaniasis
Chagas disease (American trypanosomiasis)
African trypanosomiasis
Malaria
Toxoplasmosis
Amoebiasis
Staphylococcus aureus infection
Tuberculosis
Epstein-Barr virus infection
Asthma
Autoimmune thyroid disease
Inflammatory bowel disease (IBD)
Systemic lupus erythematosus
Allograft rejection
NetPath Pathway TCR Signaling Pathway
BCR Signaling Pathway
IL2 Signaling Pathway
IL4 Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
IL4-mediated signaling events
AP-1 transcription factor network
WikiPathways SIDS Susceptibility Pathways
Cytokines and Inflammatory Response
Allograft Rejection
References
Ref 524564ClinicalTrials.gov (NCT02009449) A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 550272Clinical pipeline report, company report or official report of ARMO BioSciences.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.